FDA approves IND application for switchable CAR T-cell therapy

Calibr received approval from the FDA to move forward with an investigational new drug to treat relapsed/refractory B-cell malignancies with a switchable CAR T-cell therapy.

Source: CancerNetwork - February 7, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news